ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
Zuellig Pharma Unveils State-of-the-art Clinical Trial Support Innovation Center in South Korea to Support both Domestic and Global Clinical Research Needs
Zuellig Pharma, a leading healthcare solutions company in Asia, today announced the…
